Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 520 entries
View as:

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Phase: N/A Priority: Normal
NCT ID: NCT05316116 Org: User:
Start: 02/15/23 End: 11/17/27 Due: 11/17/28

PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

Phase: N/A Priority: Normal
NCT ID: NCT03295695 Org: User:
Start: 12/31/20 End: 12/31/22 Due: 12/31/23

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00606008 Org: User:
Start: 03/31/07 End: 08/31/12 Due: 08/31/13

R115777 in Treating Patients With Advanced Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006376 Org: User:
Start: 03/31/00 End: 05/31/05 Due: 05/31/06

Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal
NCT ID: NCT01324180 Org: User:
Start: 07/18/11 End: 07/27/17 Due: 07/27/18

Navigator Guided e-Psychoeducational Intervention

Phase: N/A Priority: Normal
NCT ID: NCT02186444 Org: User:
Start: 06/02/14 End: 08/17/17 Due: 08/17/18

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Phase: N/A Priority: Normal
NCT ID: NCT00307086 Org: User:
Start: 06/30/05 End: 03/31/12 Due: 03/31/13

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00215956 Org: User:
Start: 11/30/01 End: 01/31/08 Due: 01/31/09

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Phase: N/A Priority: Normal
NCT ID: NCT00104728 Org: User:
Start: 10/31/04 End: 03/31/09 Due: 03/31/10

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006032 Org: User:
Start: 03/31/00 End: 04/30/01 Due: 04/30/02

Spanish-Language Smoking Cessation Trial

Phase: N/A Priority: Normal
NCT ID: NCT02945787 Org: User:
Start: 10/24/16 End: 07/31/20 Due: 07/31/21

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06409390 Org: User:
Start: 08/14/24 End: 04/30/27 Due: 04/30/28

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT05065866 Org: User:
Start: 11/18/21 End: 04/24/24 Due: 04/24/25

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01253148 Org: User:
Start: 01/31/11 End: 08/31/15 Due: 08/31/16

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00437957 Org: User:
Start: 12/31/06 End: 04/30/09 Due: 04/30/10

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

Phase: N/A Priority: Normal
NCT ID: NCT01760499 Org: User:
Start: 01/24/13 End: 04/30/17 Due: 04/30/18

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Phase: N/A Priority: Normal
NCT ID: NCT01253161 Org: User:
Start: 02/01/11 End: 03/02/23 Due: 03/02/24

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05054218 Org: User:
Start: 09/10/21 End: 08/29/22 Due: 08/29/23

Evaluating Biobanking Educational Tools

Phase: N/A Priority: Normal
NCT ID: NCT01672944 Org: User:
Start: 09/27/10 End: 09/17/21 Due: 09/17/22

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00738751 Org: User:
Start: 11/30/08 End: 02/28/15 Due: 02/28/16

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT04163718 Org: User:
Start: 11/12/19 End: 10/19/22 Due: 10/19/23

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00351039 Org: User:
Start: 07/31/06 End: 09/30/08 Due: 09/30/09

Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome

Phase: N/A Priority: Normal
NCT ID: NCT05083416 Org: User:
Start: 10/20/21 End: 02/08/24 Due: 02/08/25

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03807765 Org: User:
Start: 01/30/19 End: 03/18/25 Due: 03/18/26

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05108428 Org: User:
Start: 12/23/21 End: 10/31/26 Due: 10/31/27